Should cyclosporine be useful in renal transplant recipients affected by SARS‐CoV‐2?

Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID‐19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2020-11, Vol.20 (11), p.3173-3181
Hauptverfasser:	Rodriguez‐Cubillo, Beatriz, Higuera, Maria Angeles Moreno, Lucena, Rafael, Franci, Elena V., Hurtado, Maria, Romero, Natividad C., Moreno, Antolina R., Valencia, Daniela, Velo, Mercedes, Fornie, Iñigo S., Sanchez‐Fructuoso, Ana I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antiretroviral drugs Antiviral agents Antiviral drugs Brief Communication Brief Communications Calcineurin Calcineurin inhibitors clinical research/practice Comorbidity Coronaviridae Coronaviruses COVID-19 COVID-19 - epidemiology Cyclosporine - therapeutic use Cyclosporins Female Graft rejection Graft Rejection - prevention & control health services and outcomes research Humans Hydroxychloroquine Immunomodulation immunosuppressant Immunosuppression Immunosuppression Therapy - methods Immunosuppressive agents Immunosuppressive Agents - therapeutic use Incidence kidney disease: infectious Kidney diseases Kidney Transplantation kidney transplantation / nephrology Kidney transplants Male Mechanical ventilation Middle Aged Mycophenolic acid Pandemics Rapamycin Renal function Renal Insufficiency - epidemiology Renal Insufficiency - surgery Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Spain - epidemiology Tacrolimus TOR protein Transplant Recipients Ventilation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!